Suppr超能文献

妊娠前和妊娠期间使用抗高血压药物与孕前高血压个体严重产妇发病风险的关系。

Antihypertensive Medication Use before and during Pregnancy and the Risk of Severe Maternal Morbidity in Individuals with Prepregnancy Hypertension.

机构信息

Department of Epidemiology and Population Health, Stanford University School of Medicine, Stanford, California.

Department of Community Health Sciences, University of Manitoba, Winnipeg, Manitoba, Canada.

出版信息

Am J Perinatol. 2024 May;41(S 01):e728-e738. doi: 10.1055/s-0042-1757354. Epub 2022 Oct 19.

Abstract

OBJECTIVE

Our objective is to examine severe maternal morbidity (SMM) and patterns of antihypertensive medication use before and during pregnancy among individuals with chronic hypertension.

STUDY DESIGN

We examined 11,759 pregnancies resulting in a live birth or stillbirth to individuals with chronic hypertension and one or more antihypertensive prescription 6 months before pregnancy (Optum, 2007-17). We examined whether study outcomes were associated with the use of medication as compared to no use during pregnancy. In addition, patterns of medication use based on the Food and Drug Administration guidance and literature were evaluated. Medication use was divided into prepregnancy and during pregnancy use and classified as pregnancy recommended (PR) or not pregnancy recommended (nPR) or no medication use. SMM was defined per the Centers for Disease Control and Prevention definition of 21 indicators. Risk ratios (RR) reflecting the association of SMM with the use of antihypertensive medications were computed using modified Poisson regression with robust standard errors and adjusted for maternal age, education, and birth year.

RESULTS

Overall, 83% of individuals filled an antihypertensive prescription during pregnancy and 6.3% experienced SMM. The majority of individuals with a prescription prior to pregnancy had a prescription for the same medication in pregnancy. Individuals with any versus no medication use in pregnancy had increased adjusted RR (aRR) of SMM (1.18, 95% confidence interval [CI]: 0.96-1.44). Compared to the use of PR medications before and during pregnancy, aRRs were 1.42 (95% CI: 1.18-1.69, 12.4% of sample) for nPR use before and during pregnancy, 1.52 (1.23-1.86; 12.4%) for nPR (before) and PR (during) use, and 2.67 (1.73-4.15) for PR and nPR use. Patterns with no medication use during pregnancy were not statistically significant.

CONCLUSION

Pattern of antihypertensive medication use before and during pregnancy may be associated with an elevated risk of SMM. Further research is required to elucidate whether this association is related to the severity of hypertension, medication effectiveness, or suboptimal quality of care.

KEY POINTS

· Individuals with any medication use compared to no medication use in pregnancy had an increased risk of SMM.. · Specific medication use patterns were associated with an elevated risk of SMM.. · Pattern of antihypertensive medication use before and during pregnancy may be associated with an increased risk of SMM..

摘要

目的

本研究旨在探讨慢性高血压患者在妊娠前和妊娠期间严重孕产妇发病率(SMM)和降压药物使用模式。

研究设计

我们对 11759 例妊娠(活产或死胎)进行了研究,这些妊娠来自于在妊娠前 6 个月有慢性高血压且至少有一种降压处方药的个体(Optum,2007-17 年)。我们研究了研究结果是否与妊娠期间药物使用有关。此外,还评估了基于食品和药物管理局指导和文献的药物使用模式。药物使用分为妊娠前和妊娠期间使用,并分为妊娠推荐(PR)或非妊娠推荐(nPR)或无药物使用。SMM 按照疾病预防控制中心 21 项指标的定义进行定义。使用校正后的 Poisson 回归和稳健标准误差,计算反映与降压药物使用相关的 SMM 风险比(RR),并根据产妇年龄、教育程度和出生年份进行调整。

结果

总体而言,83%的个体在妊娠期间开了降压药处方,6.3%的个体发生了 SMM。大多数在妊娠前有处方的个体在妊娠期间开了相同的药物。与妊娠期间无药物使用相比,妊娠期间有任何药物使用的个体调整后的 SMM 风险比(aRR)更高(1.18,95%置信区间[CI]:0.96-1.44)。与妊娠前和妊娠期间使用 PR 药物相比,妊娠前和妊娠期间使用 nPR 药物的 aRR 为 1.42(95%CI:1.18-1.69,占样本的 12.4%),妊娠前使用 nPR 药物和妊娠期间使用 PR 药物的 aRR 为 1.52(1.23-1.86;占 12.4%),妊娠前和妊娠期间使用 PR 和 nPR 药物的 aRR 为 2.67(1.73-4.15)。妊娠期间无药物使用的模式没有统计学意义。

结论

妊娠前和妊娠期间降压药物使用模式可能与 SMM 风险增加有关。需要进一步研究以阐明这种关联是否与高血压严重程度、药物有效性或护理质量欠佳有关。

关键点

·与妊娠期间无药物使用相比,妊娠期间有任何药物使用的个体 SMM 风险增加。

·特定的药物使用模式与 SMM 风险增加有关。

·妊娠前和妊娠期间降压药物使用模式可能与 SMM 风险增加有关。

相似文献

3
Antihypertensive drug therapy for mild to moderate hypertension during pregnancy.
Cochrane Database Syst Rev. 2018 Oct 1;10(10):CD002252. doi: 10.1002/14651858.CD002252.pub4.
5
In Utero Antihypertensive Medication Exposure and Neonatal Outcomes: A Data Linkage Cohort Study.
Hypertension. 2020 Mar;75(3):628-633. doi: 10.1161/HYPERTENSIONAHA.119.13802. Epub 2019 Dec 30.
6
Risk of postpartum readmission after hypertensive disorder of pregnancy and variation by discharge antihypertensive medication prescription.
Am J Obstet Gynecol. 2024 Oct;231(4):456.e1-456.e13. doi: 10.1016/j.ajog.2024.01.015. Epub 2024 Jan 25.
7
Prepregnancy Emergency Department Use and Risks of Severe Maternal and Neonatal Morbidity in Canada.
JAMA Netw Open. 2022 Sep 1;5(9):e2229532. doi: 10.1001/jamanetworkopen.2022.29532.
8
Maternal and neonatal outcomes associated with treating hypertension in pregnancy at different thresholds.
Pharmacotherapy. 2023 May;43(5):381-390. doi: 10.1002/phar.2778. Epub 2023 Feb 23.
9
Maternal hypertension, antihypertensive medication use, and the risk of severe hypospadias.
Birth Defects Res A Clin Mol Teratol. 2008 Jan;82(1):34-40. doi: 10.1002/bdra.20415.
10

引用本文的文献

1
Severe Maternal Morbidity Associated With Chronic Hypertension, Preeclampsia, and Gestational Hypertension.
JAMA Netw Open. 2025 Jan 2;8(1):e2451406. doi: 10.1001/jamanetworkopen.2024.51406.

本文引用的文献

1
Treatment for Mild Chronic Hypertension during Pregnancy.
N Engl J Med. 2022 May 12;386(19):1781-1792. doi: 10.1056/NEJMoa2201295. Epub 2022 Apr 2.
2
Recurrence of severe maternal morbidity: A population-based cohort analysis of California women.
Paediatr Perinat Epidemiol. 2021 Mar;35(2):155-161. doi: 10.1111/ppe.12714. Epub 2020 Nov 6.
4
Benzodiazepine use before conception and risk of ectopic pregnancy.
Hum Reprod. 2020 Jul 1;35(7):1685-1692. doi: 10.1093/humrep/deaa082.
6
Identifying pregnancies in insurance claims data: Methods and application to retinoid teratogenic surveillance.
Pharmacoepidemiol Drug Saf. 2019 Sep;28(9):1211-1221. doi: 10.1002/pds.4794. Epub 2019 Jul 22.
7
Severe Maternal Morbidity Among Stillbirth and Live Birth Deliveries in California.
Obstet Gynecol. 2019 Aug;134(2):310-317. doi: 10.1097/AOG.0000000000003370.
8
Risk of severe maternal morbidity in relation to prepregnancy body mass index: Roles of maternal co-morbidities and caesarean birth.
Paediatr Perinat Epidemiol. 2020 Jul;34(4):460-468. doi: 10.1111/ppe.12555. Epub 2019 May 20.
9
Racial and ethnic disparities in severe maternal morbidity prevalence and trends.
Ann Epidemiol. 2019 May;33:30-36. doi: 10.1016/j.annepidem.2019.02.007. Epub 2019 Feb 28.
10
Use of Medication for Cardiovascular Disease During Pregnancy: JACC State-of-the-Art Review.
J Am Coll Cardiol. 2019 Feb 5;73(4):457-476. doi: 10.1016/j.jacc.2018.10.075.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验